Tamtam Try Tamtam free
Novo Nordisk logo

Novo Nordisk account plan

Healthcare solutions for diabetes

At a glance

Novo Nordisk is a Danish obesity and diabetes drugmaker (Ozempic, Wegovy) with DKK 309,064 million of 2025 net sales and 69,505 employees.

Novo Nordisk is a Danish healthcare company founded in 1923 that develops, manufactures and sells treatments for obesity, diabetes and rare blood and endocrine disorders, built on semaglutide (Ozempic, Rybelsus, Wegovy, Wegovy pill). Its medicines reached 45.6 million people in 2025, and 99.1% of sales are realised outside Denmark. FY 2025 net sales were DKK 309,064 million (+10% at CER), operating profit DKK 127,658 million and net profit DKK 102,434 million. It had 69,505 employees at end 2025. The company is controlled by the Novo Nordisk Foundation through Novo Holdings A/S, and its B shares trade on Nasdaq Copenhagen and as ADRs on the NYSE.

Business units

Strategic priorities

Focus on obesity and diabetes
The strategy was refocused in 2025 on leading in obesity, diabetes and related comorbidities through patient centricity, innovation and affordable access, plus rare blood and endocrine disorders.
Full obesity portfolio
Build options across efficacy, delivery and price: Wegovy pill (16.6% weight loss), Wegovy 7.2 mg (20.7%), CagriSema (US decision expected end 2026), cagrilintide and zenagamtide in phase 3.
US access and direct-to-consumer
Reach patients through NovoCare Pharmacy, telehealth partners, CVS, Amazon Pharmacy and subscriptions, with self-pay prices from USD 149-299 a month for the pill and a US list price of USD 675 for Wegovy and Ozempic from 1 January 2027.
Transformation and savings
About 9,000 jobs cut for around DKK 8 billion of annual savings from 2026, redirected to obesity and diabetes; the savings are ahead of plan.
Manage semaglutide loss of exclusivity
Outside the US, launch second brands in lower-priced segments, fast-track devices and sharpen channels as semaglutide loses exclusivity in markets such as Canada, Brazil and China.

Latest results

In H1 2026 adjusted sales were DKK 148,551 million, +2% at CER, with Q2 adjusted sales of DKK 78,488 million, +7% at CER, and Q2 adjusted operating profit of DKK 33,389 million, +11%. Reported Q2 operating profit fell 16% after DKK 6.3 billion of pipeline impairments. US Operations adjusted sales fell 4% at CER on lower prices while International Operations grew 8%, with obesity care +40%. The Wegovy pill passed 5 million US prescriptions since its January launch. Guidance was raised to 0% to -6% at CER for adjusted sales and operating profit growth, with free cash flow of DKK 45-55 billion.

Investments and deals

Manufacturing capacity
Capex of DKK 60.1 billion in 2025 for API and fill-finish capacity and around DKK 55 billion planned for 2026; about USD 2 billion invested in US manufacturing in 2025 and a further USD 5.6 billion planned towards 2028.
Akero acquisition
Intangible asset purchases of DKK 30.0 billion in 2025, mainly Akero Therapeutics and its phase 3 MASH candidate efruxifermin.
In-licensing
UBT251 from The United Laboratories, four oral programmes from Septerna, zaltenibart from Omeros and Lexicon's LX9851.
Shareholder returns
A dividend of DKK 11.70 per share for 2025 and a share buyback of up to DKK 15 billion over 12 months; DKK 41.2 billion returned in H1 2026.

Challenges and risks

Lower US prices
The MFN agreement, a growing self-pay mix (about 35% of injectable Wegovy) and market-access investment cut realised prices; injectable Wegovy US sales fell 22% at CER in Q2 2026.
Semaglutide dependency and loss of exclusivity
Semaglutide is the vast majority of revenue, and its exclusivity ends in some markets in 2026, with the China compound patent expiring that year.
Competition and compounders
Branded competitors and mass compounders compete in a market the CEO likens to fast consumer goods; CagriSema trailed tirzepatide in a head-to-head study.
Pipeline setbacks
The ZEUS trial of ziltivekimab missed its primary endpoint, monlunabant was terminated, and Evoke in Alzheimer's failed.
Margin pressure
The Q2 2026 adjusted gross margin fell to 78.2% from 82.7% on lower prices and about DKK 3 billion of one-time costs to right-size manufacturing capacity agreements.

What leadership says

“The Wegovy® product portfolio remains a key growth driver for Novo Nordisk in 2026, led by the continued rapid adoption of Wegovy® pill in the US”

Maziar Mike Doustdar, President and CEO · Financial report for the first six months of 2026, 4 August 2026

“price reduction in some ways, is our investment for the future and for capturing more patients”

Maziar Mike Doustdar, President and CEO · Full year 2025 earnings call, 4 February 2026

“I don't measure our ambition by the number or the size of the acquisition we make.”

Maziar Mike Doustdar, President and CEO · Q2 2026 earnings call, 5 August 2026

“Obesity does not kill. Conditions and complications related to obesity kill”

Maziar Mike Doustdar, President and CEO · Fierce Pharma interview, 11 June 2026

Where a supplier can help

Consumer-style commercial capabilities
With obesity behaving like a consumer market and a growing self-pay and direct-to-consumer channel, digital marketing, telehealth, pharmacy and subscription partners fit the US access priority.
Manufacturing and supply chain
Capex of around DKK 55 billion in 2026, US plant investments and the Wegovy pill's ex-US rollout create demand for API, fill-finish, automation and logistics suppliers.
Cost efficiency after restructuring
The DKK 8 billion savings programme and lower sales and distribution costs favour vendors that cut operating and commercial costs.
R&D productivity
The merged R&D organisation uses AI and digital tools, and pipeline setbacks raise the value of trial design, data and clinical operations partners.
IT security
Class actions following a June 2026 IT security incident point to demand for security and incident-response services.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Novo Nordisk?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Novo Nordisk

What does Novo Nordisk do?

Novo Nordisk develops, manufactures and sells treatments for obesity and diabetes, such as Ozempic and Wegovy, and for rare blood and endocrine disorders.

What was Novo Nordisk's revenue in 2025?

Net sales were DKK 309,064 million in 2025, +10% at CER, with operating profit of DKK 127,658 million.

How many employees does Novo Nordisk have?

Novo Nordisk had 69,505 employees at end 2025; full-time employees were around 66,700 by Q2 2026 after the restructuring.

What is Novo Nordisk's strategy?

It has refocused on obesity and diabetes, building a full obesity portfolio of injectables and pills, widening US access through direct-to-consumer channels and cutting about 9,000 jobs to fund growth.

Who leads Novo Nordisk?

Maziar Mike Doustdar has been President and CEO since 2025, Karsten Munk Knudsen is CFO, and Lars Rebien Sørensen chairs the Board.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)